Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor

doi:10.1016/j.neulet.2012.01.022

Neuroscience Letters

Volume 510, Issue 2, 29 February 2012, Pages 138-142

https://doi.org/10.1016/j.neulet.2012.01.022 Get rights and content

Abstract

Reactive gliosis and inflammatory change is a key component of nigral dopaminergic cell death in Parkinson's disease (PD). Astrocyte derived glial cell line-derived neurotrophic factor (GDNF) promotes the survival and growth of dopaminergic neurones and it protects against or reverses nigral degeneration induced by 6-OHDA and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rodents and primates. But the effect of increased levels of pro-inflammatory cytokines on the release of GDNF is unknown. This study examined the relationship between release of tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) and the expression of GDNF in rats following nigral lipopolysaccharide (LPS) administration. Acute nigral administration of LPS led to marked elevation of IL-1β but insignificant TNF-α tissue content and to a prominent expression of GDNF immunoreactivity in astrocytes but not microglia. The results suggest that inflammation is not only involved in neuronal loss but could promote neuronal survival through increased release of GDNF following up-regulation of IL-1β.

Highlights

► At 24 h following nigral LPS, IL-1β but TNF-α was insignificantly release. ► LPS treatment led to astrocytic but not microglial expression of GDNF. ► Increased expression and release of GDNF and IL-1β may promote neuronal survival.

References (44)

M.L. Block et al.
Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism
Prog. Neurobiol.
(2005)
M. Bresjanac et al.
Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo
Exp. Neurol.
(2000)
D.L. Choi-Lundberg et al.
Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat
Brain Res. Dev. Brain Res.
(1995)
D.A. Gayle et al.
(LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide
Brain Res. Dev. Brain Res.
(2002)
E.C. Hirsch et al.
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Lancet Neurol.
(2009)
T. Inoue et al.
Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment
Brain Res.
(1999)
M.M. Iravani et al.
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration
Neuroscience
(2002)
M.M. Iravani et al.
Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response
Exp. Neurol.
(2008)
R. Kuno et al.
The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes
Brain Res.
(2006)
A.E. Lang et al.
GDNF in treatment of Parkinson's disease: response to editorial
Lancet Neurol.
(2006)

B. Marchetti et al.

To be or not to be (inflamed)—is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?

Trends Pharmacol. Sci.

(2005)

S. Marco et al.

Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum

Exp. Neurol.

(2002)

K.S. McNaught et al.

Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release

Neurosci. Lett.

(2000)

M. Mogi et al.

Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506

Neurosci. Lett.

(2000)

B. Ossola et al.

Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia

Neuropharmacology

(2011)

N.J. Rothwell et al.

Interleukin 1 in the brain: biology, pathology and therapeutic target

Trends Neurosci.

(2000)

A. Saavedra et al.

Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures

Neurobiol. Dis.

(2007)

A. Saavedra et al.

Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk

Neurobiol. Dis.

(2006)

T. Wyss-Coray et al.

Inflammation in neurodegenerative disease—a double-edged sword

Neuron

(2002)

D.M. Yurek et al.

Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion

Brain Res.

(2001)

A. Anastasia et al.

Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease

J. Neurochem.

(2007)

E. Appel et al.

Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli

Neuroreport

(1997)

Cited by (41)

Bruceine D elevates Nrf2 activation to restrain Parkinson's disease in mice through suppressing oxidative stress and inflammatory response
2020, Biochemical and Biophysical Research Communications
Parkinson’s disease (PD) is neurodegenerative disease, featured by a loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), characteristic motor symptoms and cognitive impairment. Development of effective therapeutic drugs for PD is necessary. In this study, we investigated the potential of Bruceine D (BD) during PD progression. After establishment of PD mouse models, we found that BD markedly improved the motor function of mice and alleviated chemically induced dopaminergic neuron loss of tyrosine hydroxylase (TH) in the SNpc area. BD treatments markedly repressed the neuroinflammation in SNpc by restricting nuclear factor κB (NF-κB) activation, accompanied with the reduced activity of astrocytes and microglial. BD also improved the antioxidant system in MPTP-challenged mice, as proved by the up-regulated superoxide dismutase (SOD) and glutathione (GSH), and down-regulated malondialdehyde (MDA) in SNpc and striatum (STR). The anti-oxidant effects of BD were regulated by the activation of nuclear factor E2-related factor 2 (Nrf2) signaling, contributing to the expression of Nrf2 down-streaming signals such as heme oxygenase-1 (HO-1), NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutathione cysteine ligase modulatory subunit (GCLM). In MPP⁺-challenged mouse neurons, BD exhibited cytoprotective effects by improving the Nrf2-meditated antioxidant system and abolished the MPP⁺-triggered inflammatory response through hindering the activation of the NF-κB signal. The pharmacokinetic parameters and organ distribution findings demonstrated that BD showed a brain tissue targeting function. Moreover, both in vivo and in vitro analysis indicated that BD had few side effects. Collectively, results here demonstrated that BD was effective for the inhibition of dopaminergic neuronal loss and PD progression by activating Nrf2 without toxicity.
Mitochondrial control of cell bioenergetics in Parkinson's disease
2016, Free Radical Biology and Medicine
Citation Excerpt :
Microglial activation has thus been observed in both sporadic and familial PD patients [73]. Microglial activation in turn leads to increased cytokine formation, ROS production and decreased secretion of trophic factors, inducing neuronal death [66,74,75]. Toxins, such as MPTP and rotenone, as well as mutations of PD-associated proteins like α-synuclein, Parkin, Pink1, DJ-1 and LRRK2, have been reported to activate glial cells and release ROS, inducing astrocyte activation thus amplifying the pro-inflammatory response and increasing microglial phagocytosis [76–79].
Parkinson disease (PD) is a neurodegenerative disorder characterized by a selective loss of dopaminergic neurons in the substantia nigra. The earliest biochemical signs of the disease involve failure in mitochondrial-endoplasmic reticulum cross talk and lysosomal function, mitochondrial electron chain impairment, mitochondrial dynamics alterations, and calcium and iron homeostasis abnormalities. These changes are associated with increased mitochondrial reactive oxygen species (mROS) and energy deficiency. Recently, it has been reported that, as an attempt to compensate for the mitochondrial dysfunction, neurons invoke glycolysis as a low-efficient mode of energy production in models of PD. Here, we review how mitochondria orchestrate the maintenance of cellular energetic status in PD, with special focus on the switch from oxidative phosphorylation to glycolysis, as well as the implication of endoplasmic reticulum and lysosomes in the control of bioenergetics.
6-Hydroxydopamine and lipopolysaccharides induced DNA damage in astrocytes: Involvement of nitric oxide and mitochondria
2015, Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Citation Excerpt :
The neuroprotective and neurodegenerative roles of astrocytes depend largely on the molecules that they release into and take up from the extracellular space. Astrocytes release neurotrophic factors along with various neurotoxic factors like proinflammatory cytokines and increased ROS generation [13–17]. Evidence of astrogliosis in animal models and human post mortem studies of neurological disorders has been reported and showed their association in neuronal death [18–21].
The present study was conducted to investigate the effect of the neurotoxins 6-hydroxydopamine and lipopolysaccharide on astrocytes. Rat astrocyte C6 cells were treated with different concentration of 6-hydroxydopamine (6-OHDA)/lipopolysaccharides (LPS) for 24 h. Both neurotoxins significantly decreased the viability of astrocytes, augmented the expression of inducible nitric oxide synthase (iNOS) and the astrocyte marker – glial fibrillar acidic protein. A significantly decreased mitochondrial dehydrogenase activity, mitochondrial membrane potential, augmented reactive oxygen species (ROS) level, caspase-3 mRNA level, chromatin condensation and DNA damage was observed in 6-OHDA/LPS treated astroglial cells. 6-OHDA/LPS treatment also caused the significantly increased expression of iNOS and nitrite level. Findings showed that 6-OHDA/LPS treatment caused mitochondrial dysfunction mediated death of astrocytes, which significantly involve the nitric oxide. Since we have observed significantly increased level of iNOS along with mitochondrial impairment and apoptotic cell death in astrocytes, therefore to validate the role of iNOS, the cells were co-treated with iNOS inhibitor aminoguanidine (AG, 100 μM). Co-treatment of AG significantly attenuated the 6-OHDA/LPS induced cell death, mitochondrial activity, augmented ROS level, chromatin condensation and DNA damage. GFAP and caspase-3 expression were also inhibited with co-treatment of AG, although the extent of inhibition was different in both experimental sets. In conclusion, the findings showed that iNOS mediated increased level of nitric oxide acts as a key regulatory molecule in 6-OHDA/LPS induced mitochondrial dysfunction, DNA damage and apoptotic death of astrocytes.
In vitro biocompatibility evaluation of functional electrically stimulating microelectrodes on primary glia
2024, Frontiers in Bioengineering and Biotechnology
THE EFFECT OF VITIS VINIFERA L EXTRACT ON EMOTIONAL AND BEHAVIORAL STATUS, OXIDATIVE STRESS AND INFLAMMATION IN A RODENT MODEL OF SURGICAL INDUCED MENOPAUSE
2023, Farmacia
The Role of eIF5A1 in LPS-Induced Neuronal Remodeling of the Nucleus Accumbens in the Depression
2023, Journal of Integrative Neuroscience

View all citing articles on Scopus

View full text

Lipopolysaccharide-induced nigral inflammation leads to increased IL-1β tissue content and expression of astrocytic glial cell line-derived neurotrophic factor

Abstract

Highlights

Prog. Neurobiol.

Exp. Neurol.

Brain Res. Dev. Brain Res.

Brain Res. Dev. Brain Res.

Lancet Neurol.

Brain Res.

Neuroscience

Exp. Neurol.

Brain Res.

Lancet Neurol.

Trends Pharmacol. Sci.

Exp. Neurol.

Neurosci. Lett.

Neurosci. Lett.

Neuropharmacology

Trends Neurosci.

Neurobiol. Dis.

Neurobiol. Dis.

Neuron

Brain Res.

Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease

J. Neurochem.

Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli

Neuroreport